Actualités Timber Pharmaceuticals Inc - TMBR | Actions American Stock Exchange

Timber Pharmaceuticals, Inc. Announces 1-for-50 Reverse Stock Split

BASKING RIDGE, NJ, Nov. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE...

Current Report Filing (8-k)

0001504167 false 0001504167 2022-11-03 2022-11-03 iso4217:USD xbrli:shares...

Timber Pharmaceuticals Announces Halt of Common Stock Trading

Compliance with NYSE Listing Requirements Contingent on Stockholder Approval of Reverse Stock Split at Special...

Current Report Filing (8-k)

0001504167false00015041672022-10-252022-10-25J UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM...

Timber Pharmaceuticals Receives European Orphan Designation for Autosomal Recessive Congenital Ichthyosis & Positive Comments on Pediatric Investigation Plan for TMB-001 in Autosomal Recessive CI & X-Linked Recessive Ichthyosis

- Regulatory Milestones Improve Path to Filing a European Marketing Authorization Application -- Company Plans...

Current Report Filing (8-k)

0001504167false--12-3100015041672022-10-032022-10-03J UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM...

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

Filed Pursuant to Rule 424(b)(5) Registration No. 333-255743 PROSPECTUS...

Timber Pharmaceuticals Announces $1.3 Million Registered Direct Offering

BASKING RIDGE, NJ, Oct. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc...

Timber Pharmaceuticals Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital Ichthyosis

European Commission expected to issue its decision on orphan designation in approximately 30 days BASKING...

Timber Pharmaceuticals Announces Publication of Results from Phase 2b CONTROL Study of FDA-Designated Breakthrough Therapy TMB-001 in the Journal of the American Academy of Dermatology

- Previously reported study demonstrated clinically meaningful efficacy with a favorable safety profile for...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Timber Pharmaceuticals Inc (TMBR)

Votre Hub pour des idées et discussions en direct en temps réel

TMBR Actualités

Timber Pharmaceuticals, Inc. Announces 1-for-50 Reverse Stock Split

Current Report Filing (8-k)

Timber Pharmaceuticals Announces Halt of Common Stock Trading

Current Report Filing (8-k)

Timber Pharmaceuticals Receives European Orphan Designation for Autosomal Recessive Congenital Ichthyosis & Positive Comments on Pediatric Investigation Plan for TMB-001 in Autosomal Recessive CI & X-Linked Recessive Ichthyosis

Current Report Filing (8-k)

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

Timber Pharmaceuticals Announces $1.3 Million Registered Direct Offering

Timber Pharmaceuticals Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital Ichthyosis

Current Report Filing (8-k)

Current Report Filing (8-k)

Current Report Filing (8-k)

Timber Pharmaceuticals Announces Notification of NYSE American Continued Listing Deficiency

Timber Pharmaceuticals to Highlight Phase 2b CONTROL Study Results in Multiple Presentations at 31st EADV Congress

Timber Pharmaceuticals Announces Publication of Results from Phase 2b CONTROL Study of FDA-Designated Breakthrough Therapy TMB-001 in the Journal of the American Academy of Dermatology

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Timber Pharmaceuticals Inc (TMBR) Actualités

Timber Pharmaceuticals Inc (TMBR)

Votre Hub pour des idées et discussions en direct en temps réel

TMBR Actualités

Timber Pharmaceuticals, Inc. Announces 1-for-50 Reverse Stock Split

Current Report Filing (8-k)

Timber Pharmaceuticals Announces Halt of Common Stock Trading

Current Report Filing (8-k)

Timber Pharmaceuticals Receives European Orphan Designation for Autosomal Recessive Congenital Ichthyosis & Positive Comments on Pediatric Investigation Plan for TMB-001 in Autosomal Recessive CI & X-Linked Recessive Ichthyosis

Current Report Filing (8-k)

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

Timber Pharmaceuticals Announces $1.3 Million Registered Direct Offering

Timber Pharmaceuticals Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital Ichthyosis

Current Report Filing (8-k)

Current Report Filing (8-k)

Current Report Filing (8-k)

Timber Pharmaceuticals Announces Notification of NYSE American Continued Listing Deficiency

Timber Pharmaceuticals to Highlight Phase 2b CONTROL Study Results in Multiple Presentations at 31st EADV Congress

Timber Pharmaceuticals Announces Publication of Results from Phase 2b CONTROL Study of FDA-Designated Breakthrough Therapy TMB-001 in the Journal of the American Academy of Dermatology

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application